Michael Untch, David Pérol, Erica L Mayer, Javier Cortes, Arnd Nusch, David Cameron, Carlos Barrios, Thomas Delea, Andrii Danyliv, Namita Mishra, Rhea Gupta, Purnima Pathak, Peter A Fasching
BACKGROUND: Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC...
March 1, 2024: European Journal of Cancer